Joining Forces for Mutual Success | Xiuwei Technology, Yice Technology and Qianyun Data Reach a Three-Party Strategic Partnership
In the midsummer of July, major industry events followed one after another. During the 2026 World Artificial Intelligence Conference, Mr. Chen Jun, Chairman of Guangzhou Xiuwei Technology Co., Ltd., was invited to Shanghai to attend the event. He engaged in in-depth exchanges with fellow professionals in the medical technology sector, explored the latest trends in AI-enabled digital transformation in pathology, and gained insights into common industry challenges amid healthcare insurance reform.
Building on their deep understanding of industry trends and shared vision for cooperation, Xiuwei Technology, Yice Technology, and Qianyun Data officially held a three-party strategic cooperation signing ceremony in Hangzhou on July 20.
The three parties will integrate their core capabilities in three key areas—full-industry-chain hardware, pathology AI technology, and data security architecture—to jointly develop a one-stop comprehensive solution tailored to China's new medical insurance reimbursement policies for pathology services. The collaboration aims to help medical institutions at all levels address compliance pressures and development challenges arising from healthcare insurance reform.
Responding to Industry Changes: Addressing Four Major Challenges Facing Pathology Departments Under Healthcare Insurance Reform
In 2026, China's new medical insurance reimbursement policies for pathology services were fully implemented, bringing significant changes to industry regulations. In many regions, separate charges for fragmented slide preparation and staining procedures have been eliminated. For slides that have not been digitally uploaded, a deduction of RMB 5 per slide will be imposed, with a maximum deduction of RMB 15 per examination.
Under these policy adjustments, pathology departments at hospitals across China are facing four major challenges:
l High risk of compliance-related deductions, with non-digitized slides directly resulting in revenue loss;
l Adjustments to the reimbursement structure, shrinking traditional business revenue and creating limited opportunities for revenue growth;
l Widespread data silos, with disconnected internal hospital systems and potential security risks in external data transmission;
l Limited diagnostic capabilities at primary-level healthcare institutions, hindering the balanced development of regional healthcare services.
Based on a shared understanding of these common industry challenges, Xiuwei Technology, Yice Technology, and Qianyun Data engaged in in-depth discussions and collaboration during the World Artificial Intelligence Conference. The three parties ultimately reached a strategic partnership, leveraging cross-industry collaboration to provide the pathology sector with a systematic solution to these challenges.
Joining Forces: Building a Full-Process Digital Solution Through Three-Party Collaboration
Leveraging Xiuwei Technology's integrated full-industry-chain hardware and software capabilities, Yice Technology's strengths in pathology AI and quality control systems, and Qianyun Data's expertise in data security and storage technologies, the three parties will jointly implement a comprehensive service system covering compliance risk mitigation, value-added revenue growth, data security, AI empowerment, and full-chain support, fully responding to the requirements of digital transformation under healthcare insurance reform.
1. Full-Process Standardization to Prevent Healthcare Insurance Deductions at the Source
With Xiuwei Technology's comprehensive range of pathology equipment—including fully enclosed tissue processors, microtomes, tissue embedding centers, slide stainers and coverslippers, and digital slide scanners—as the hardware foundation, the three parties will establish a standardized workflow covering slide preparation, staining, and scanning.
This integrated workflow will ensure the stable production of high-definition digital slides that meet healthcare insurance archiving standards, preventing the RMB 5 deduction per slide at the source.
In conjunction with the Qianyun Pathology Cloud Platform, the entire workflow will be automatically logged and documented. The system will automatically capture records throughout the entire process, including specimen receipt, fixation, tissue processing, staining, and scanning, as well as reagent batch numbers, personnel information, and timestamps.
These digital records provide complete traceability and can be retrieved with one click during healthcare insurance audits, helping laboratories avoid compliance-related penalties.
The solution also provides high-speed batch scanning and digitization services for existing glass slides, rapidly completing historical electronic archives, ensuring that the department's existing diagnostic revenue can be fully settled, and helping hospitals successfully meet annual healthcare insurance digitalization assessment requirements.
2. Full-Industry-Chain Support to Ensure Compliance Throughout the Entire Workflow
As a leading pathology supply chain manufacturer in China and international markets, Xiuwei Technology offers a comprehensive product portfolio covering pathology laboratory instruments, consumables, and reagents.
With strong R&D and manufacturing capabilities, as well as a well-established service network across China and global markets, Xiuwei Technology provides a solid hardware foundation and channel support for the implementation of the solution.
Moving Forward Together: Building a New Era of High-Quality Development for the Pathology Industry
The establishment of this three-party strategic partnership marks an important milestone in collaborative innovation across the pathology industry chain.
Taking this partnership as an opportunity, Xiuwei Technology will continue to focus on pathology equipment manufacturing, continuously strengthen product innovation and service capabilities, and work together with its partners to provide medical institutions across China with higher-quality and more efficient comprehensive pathology solutions.
Together, the three parties will help China's pathology sector move toward a new stage of intelligent and digital development.
Looking ahead, the three parties will fully leverage their respective strengths, deepen cooperation, expand the scope of collaboration, and drive industrial upgrading through technological innovation.
Together, they will promote the development of a smart pathology ecosystem and contribute to the advancement of precision medicine.
